Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study

NCT01126424 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01126424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01126424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2010
Completion date
December 31, 2010
Enrollment
26 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cognition